These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 26453168)

  • 1. Low molecular weight chitosan-coated polymeric nanoparticles for sustained and pH-sensitive delivery of paclitaxel.
    Abouelmagd SA; Ku YJ; Yeo Y
    J Drug Target; 2015; 23(7-8):725-35. PubMed ID: 26453168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor.
    Yang R; Shim WS; Cui FD; Cheng G; Han X; Jin QR; Kim DD; Chung SJ; Shim CK
    Int J Pharm; 2009 Apr; 371(1-2):142-7. PubMed ID: 19118614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery.
    Parveen S; Sahoo SK
    Eur J Pharmacol; 2011 Nov; 670(2-3):372-83. PubMed ID: 21951969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Preparation and drug release property of paclitaxel nanoparticles].
    Wang TW; Wu Y; Li MJ; Gao HX
    Zhong Yao Cai; 2009 Sep; 32(9):1447-9. PubMed ID: 20034226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low Molecular Weight Chitosan-Coated PLGA Nanoparticles for Pulmonary Delivery of Tobramycin for Cystic Fibrosis.
    Al-Nemrawi NK; Alshraiedeh NH; Zayed AL; Altaani BM
    Pharmaceuticals (Basel); 2018 Mar; 11(1):. PubMed ID: 29517998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low molecular-weight chitosan as a pH-sensitive stealth coating for tumor-specific drug delivery.
    Amoozgar Z; Park J; Lin Q; Yeo Y
    Mol Pharm; 2012 May; 9(5):1262-70. PubMed ID: 22489704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lung-specific delivery of paclitaxel by chitosan-modified PLGA nanoparticles via transient formation of microaggregates.
    Yang R; Yang SG; Shim WS; Cui F; Cheng G; Kim IW; Kim DD; Chung SJ; Shim CK
    J Pharm Sci; 2009 Mar; 98(3):970-84. PubMed ID: 18661542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study on chitosan-modified tripterygium glycoside nanoparticles and its renal targeting property].
    Chen XK; Wei YH; Yao JN; Zhao YM; Shang XG; Li FZ
    Zhongguo Zhong Yao Za Zhi; 2013 Feb; 38(4):548-52. PubMed ID: 23713281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polydopamine-based surface modification for the development of peritumorally activatable nanoparticles.
    Gullotti E; Park J; Yeo Y
    Pharm Res; 2013 Aug; 30(8):1956-67. PubMed ID: 23609560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of poly(ethylene glycol) grafting density on the tumor targeting efficacy of nanoparticles with ligand modification.
    Zhang S; Tang C; Yin C
    Drug Deliv; 2015 Feb; 22(2):182-90. PubMed ID: 24215373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative evaluation of novel biodegradable nanoparticles for the drug targeting to breast cancer cells.
    Mattu C; Pabari RM; Boffito M; Sartori S; Ciardelli G; Ramtoola Z
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):463-72. PubMed ID: 23916461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule delivery to solid tumors with chitosan-coated PLGA particles: A lesson learned from comparative imaging.
    Park J; Pei Y; Hyun H; Castanares MA; Collins DS; Yeo Y
    J Control Release; 2017 Dec; 268():407-415. PubMed ID: 29111150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and characterization of tumor-targeted copolymer nanocarrier modified by transferrin.
    Liu R; Wang Y; Li X; Bao W; Xia G; Chen W; Cheng J; Xu Y; Guo L; Chen B
    Drug Des Devel Ther; 2015; 9():2705-19. PubMed ID: 26045659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Photopolymerized Semi-Interpenetrating Polymer Networks-Based Hydrogel Incorporated with Nanoparticle for Local Chemotherapy of Tumors.
    Wang Y; Li Q; Zhou JE; Tan J; Li M; Xu N; Qu F; Chen J; Li J; Wang J; Liang Z; Yu L; Wang Y; Yan Z
    Pharm Res; 2021 Apr; 38(4):669-680. PubMed ID: 33796952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chitosan film containing poly(D,L-lactic-co-glycolic acid) nanoparticles: a platform for localized dual-drug release.
    Tada DB; Singh S; Nagesha D; Jost E; Levy CO; Gultepe E; Cormack R; Makrigiorgos GM; Sridhar S
    Pharm Res; 2010 Aug; 27(8):1738-45. PubMed ID: 20521086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic((R))P85, an in vitro cell line and in vivo biodistribution studies on rat model.
    Shah N; Chaudhari K; Dantuluri P; Murthy RS; Das S
    J Drug Target; 2009 Aug; 17(7):533-42. PubMed ID: 19530913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. pH-Sensitive Biocompatible Nanoparticles of Paclitaxel-Conjugated Poly(styrene-co-maleic acid) for Anticancer Drug Delivery in Solid Tumors of Syngeneic Mice.
    Dalela M; Shrivastav TG; Kharbanda S; Singh H
    ACS Appl Mater Interfaces; 2015 Dec; 7(48):26530-48. PubMed ID: 26528585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-layer surface coating of PLGA-based nanoparticles provides slow-release drug delivery to achieve metronomic therapy in a paclitaxel-resistant murine ovarian cancer model.
    Amoozgar Z; Wang L; Brandstoetter T; Wallis SS; Wilson EM; Goldberg MS
    Biomacromolecules; 2014 Nov; 15(11):4187-94. PubMed ID: 25251833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycyrrhizin conjugated chitosan nanoparticles for hepatocyte-targeted delivery of lamivudine.
    Mishra D; Jain N; Rajoriya V; Jain AK
    J Pharm Pharmacol; 2014 Aug; 66(8):1082-93. PubMed ID: 24641311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells.
    Gao C; Pan J; Lu W; Zhang M; Zhou L; Tian J
    Anticancer Drugs; 2009 Oct; 20(9):807-14. PubMed ID: 19696655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.